

## **Publications**

### **1. Antipsychotic-induced motor disorders: clinical characteristics and treatment**

**Poyurovsky M**, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. *Br J Psychiatry*. 2001; 179:184. (Invited Review). [IF 5.446]

**Poyurovsky M**. Acute antipsychotic-induced akathisia revisited. *Br J Psychiatry*. 2010 Feb; 196 (2):89-91. (Invited editorial).

#### Book chapters:

Stryjer R, Strous RD, Shiloh R, **Poyurovsky M**, Weizman A. "5HT2a antagonists for the management of neuroleptic induced acute akathisia". "Focus on Serotonin Uptake Inhibitor Research." Nova Science Publishers, Inc., 2006.

1. **Poyurovsky M**, Shardarodsky M, Fuchs C, Schneidman M, Weizman A. Treatment of neuroleptic-induced akathisia with the 5-HT<sub>2</sub> antagonist mianserin. Double-blind, placebo-controlled study. *Br J Psychiatry* 1999; 174:238-42.
2. **Poyurovsky M**, Nave R, Epstein R, Tzischinsky O, Schneidman M, Barnes TRE, Weizman A, Lavie P. Actigraphic monitoring (Actigraphy) in circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia. *Eur Neuropsychopharmacol*, 2000, 10(3):171-176.
3. **Poyurovsky M**, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman R. Effect of the 5-HT<sub>2</sub> antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. *Eur Neuropsychopharmacol*. 2003 Mar;13(2):123-8. [IF 4.430]
4. **Poyurovsky M**, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. *J Clin Psychopharmacol*. 2003 Jun;23(3):305-8. [IF 4.561]
5. **Poyurovsky M**, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. *Biol Psychiatry*, 2006 Jun 1;59(11):1071-7. [IF 8.456]
6. Kulisevsky J, **Poyurovsky M**. Adenosine A<sub>2A</sub>-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders. *Eur Neurol*. 2012;67(1):4-11.
7. **Poyurovsky M**., Kosov A., Halperin E. Enoch D, Schneidman M, Weizman A.. Akathisia-like behavior following ECT and its successful treatment with low-dose mianserin. *Int Clin Psychopharmacol*, 1995; 10: 257-260. [IF 3.262]
8. **Poyurovsky M**., Kreinin A., Modai I., Weizman A. Lithium-induced akathisia responds to low-dose mianserin. *Int Clin Psychopharmacol*, 1995; 10: 261-263. [IF 3.262]
9. **Poyurovsky M**., Meerovich I., Weizman A. Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. *Int Clin Psychopharmacol* 1995; 10: 111-114. [IF 3.262]
10. **Poyurovsky M**., Scheidman M., Mark M., Weizman A. Verapamil treatment in clozapine-induced sleep-related enuresis: a case report. *Eur Psychiatry*, 1995; 10: 413-415. [IF 1.875]
11. **Poyurovsky M**, Halperin E., Enoch D. Schneidman M, Weizman A.. Fluvoxamine treatment of compulsivity impulsivity and aggression. *Am J Psychiatry*, 1995; 152: 1688-1689. [IF 9.127]
12. **Poyurovsky M**., Modai I, Weizman A. Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis. *Int Clin Psychopharmacol* 1996; 11: 61-3. [IF

13. **Poyurovsky M.**, Hermesh H. Weizman A. Severe withdrawal akathisia following neuroleptic discontinuation successfully controlled by clozapine. *Int Clin Psychopharmacol* 1996; 11: 283-6. [IF 3.262]
14. **Poyurovsky M.**, Weizman A. Safety and effectiveness of combined ECT and clozapine in treatment resistant mania. *Eur Psychiatry* 1996; 11:319-321. [1.875]
15. **Poyurovsky M.**, Weizman A. Lack of efficacy of the 5-HT<sub>3</sub> receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia. *Int Clin Psychopharmacol* 1999; 14(6): 357-60. [IF 3.262]
16. **Poyurovsky M.** and Weizman A. Successful treatment of fluoxetine induced dystonia with low-dose mianserin. *Movement Dis* 1997; 12:1102-5. [IF 3.207]
17. **Poyurovsky M.**, Weizman A. Selective serotonin reuptake inhibitor and akathisia. *J Clin Psychopharmacol.* 1997; 17: 489-490. [IF 4.561]
18. **Poyurovsky M.** Weizman A. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. *Intl Clin Psychopharmacol* 1997; 12: 263-8. [IF 3.262]
19. **Poyurovsky M.**, Fuchs K., Weizman A. Low-dose mianserin in the treatment of acute neuroleptic-induced akathisia. *J Clin Psychopharmacol* 1998; 18: 253-4 [IF 4.561]
20. **Poyurovsky M.**, Weizman A. Mirtazapine for neuroleptic-induced akathisia. *Am J Psychiatry.* 2001 May;158(5):819. [IF 9.127]
21. Stryjer R, Strous RD, Bar F, **Poyurovsky M.**, Weizman A, Kotler M. Treatment of neuroleptic induced akathisia with the 5HT<sub>2a</sub> antagonist trazodone. *Clin Neuropharmacol* 2003 May-Jun; 26(3):137-41. [IF 2.323]
22. Stryjer R, Grupper D, Strous R, **Poyurovsky M.**, Weizman A. Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient. *Eur Psychiatry.* 2004 Jun;19(4):237-8. [IF 1.875]
23. **Poyurovsky M.**, Fuchs C, Weizman A. Low-dose mianserin in treatment of acute neuroleptic-induced akathisia. *J Clin Psychopharmacol.* 1998 Jun;18(3):253-4. [IF 4.561]
24. **Poyurovsky M.**, Weizman A. Serotonin antagonists and neuroleptic-induced extrapyramidal symptoms. *Isr J Psychiatry Relat Sci.* 1998;35(1):70-1. [IF 0.5]
25. **Poyurovsky M.**, Weizman A. Selective serotonin reuptake inhibitor and akathisia. *J Clin Psychopharmacol.* 1997 Dec;17(6):489. [IF 4.561]
26. **Poyurovsky M.**, Weizman R, Weizman A. Aripiprazole's receptor pharmacology and extrapyramidal side effects. *Am J Psychiatry.* 2008 Mar;165(3):398; author reply 398-9. [IF 9.127]
27. **Poyurovsky M.**, Bergman J, Pashinian A, Weizman A. Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. *Int Clin Psychopharmacol.* 2014 Mar 24. [Epub ahead of print]
28. **Poyurovsky M.**, Weizman R, Weizman A. Mirtazapine - a multifunctional drug: low dose for akathisia. *CNS Spectr.* 2011 Feb;16(2):63.

## **Publications**

### **2. Treatment of obesity and Antipsychotic-induced weight gain**

29. **Poyurovsky M**, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. *Am J Psychiatry*. 2002 Jun;159(6):1058-60. [IF 9.127]
30. **Poyurovsky M**, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. *Am J Psychiatry*. 2003 Feb; 160 (2):297-302. . [IF 9.127]
31. Nechmad A, Maayan R, Ramadan E, Morad O, **Poyurovsky M**, Weizman A. Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. *Eur Neuropsychopharmacol*. 2003 Jan;13(1):29-31. [IF 4.430]
32. **Poyurovsky M**, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. *Eur Neuropsychopharmacol* 2004; 14(4):332-336. [IF 4.430]
33. **Poyurovsky M**, Pashinian A, Levi A, Weizman R, Weizman A. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. *Int Clin Psychopharmacol*. 2005 Mar;20(2):101-3.
34. **Poyurovsky M**, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. *Psychopharmacology (Berl)*. 2007 Jun;192(3):441-448. [IF 3.561]
35. Amrami-Weizman A, Maayan R, Gil-Ad I, Pashinian A, Fuchs C, Kotler M, **Poyurovsky M**. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. *Psychopharmacology (Berl)*. 2013 Nov;230(1):23-7. 
36. **Poyurovsky M**, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. *Psychopharmacology (Berl)*. 2013 Apr;226(3):615-22.

## **Publications**

### 3. Obsessive-compulsive symptoms in schizophrenia: clinical characteristics, neurobiology and treatment

#### **Book chapters**

**Poyurovsky M**, Weizman A, Weizman R. Schizo-obsessive Disorder. In: Obsessive-compulsive Spectrum Disorders, Eds: Gross-Isserof R, Weizman A., Martin Dunitz, 2006.

**Poyurovsky M**. Obsessive-Compulsive Disorder in Schizophrenia: Clinical Characterization and Treatment. In: *Clinical Obsessive-Compulsive Disorders in Adults and Children*. Eds Robert Hudak, MD; and Darin Dougherty, MD. Cambridge University Press, 2009.

#### **Invited Reviews**

37.**Poyurovsky M**, Zohar J, Glick I, Koran LM, Weizman R, Tandon R, Weizman A. Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. *Compr Psychiatry*. 2012 Jul;53(5):480-3

38.**Poyurovsky M**, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. *CNS Drugs*. 2004; 18(14):989-1010 (Invited Review). [IF 4.514]

39.**Poyurovsky M**, Koran LM. Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. *J Psychiatr Res*. 2005 Jul; 39(4):399-408. (Invited Review). [IF 3.710]

40.**Poyurovsky M**. Exploring OCD Subtypes and Treatment Resistance. *Psychiatric Times* 2007; 24 (10): September 1. (Invited Review)

41.Frisch A, Michaelovsky F, Rockah R, Amir I, Hermesh H, Laor N, Fuchs C, Zohar J, Lerer B, Buniak SF, Land S, **Poyurovsky M**, Shapira B, Weizman R. Association between obsessive-compulsive disorder and polymorphisms genes encoding components of the serotonergic and dopaminergic pathways. *Eur Neuropsychopharmacol*, 2000; 10(3):205-209.

42.**Poyurovsky M**, Kriss V, Weisman G, Faragian S, Schneidman M, Fuchs C, Weizman A, Weizman R. Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD. *Am J Med Genet B Neuropsychiatr Genet*. 2005 Feb 5; 133(1):31-6. [4.224]

43.**Poyurovsky M**, Michaelovsky E, Frisch A, Knoll G, Amir I, Finkel B, Buniak F, Hermesh H, Weizman R. COMT Val(158)Met polymorphism in schizophrenia with obsessive-compulsive disorder: A case-control study. *Neurosci Lett*. 2005 Nov 25; 389(1):21-24. [IF 2.085]

44.**Poyurovsky M**, Faragian S, Pashinian A, Levi A, Weisbort A, Stryker R, Weizman R, Fuchs R, Weizman A. Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder. *J Neuropsychiatry Clin Neurosci*. 2007 Spring;19(2):145-50 [IF 2.053]

45. **Poyurovsky M**, Fuchs C, Faragian S, Kriss V, Weisman G, Pashinian A, Weizman R, Weizman A. Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder. *Can J Psychiatry*. 2006 Oct;51(12):746-54. [IF 3.026]
46. Faragian S, Kurs R, **Poyurovsky M**. Insight into Obsessive –Compulsive Symptoms and Awareness of Illness in Adolescent Schizophrenia Patients with and without OCD. *Child Psychiatry Hum Dev*, 2008;39(1):39-48.. [IF 0.925]
47. **Poyurovsky M**, Faragian S, Kleinman-Balush V, Pashinian A, Kurs R, Fuchs C. Awareness of Illness and Insight into Obsessive-Compulsive Symptoms in Schizophrenia Patients with Obsessive-Compulsive Disorder. *J Nerv Ment Dis*, 2007;195(9):765-768.[IF 1.863]
48. Glick ID, **Poyurovsky M**, Ivanova O, Koran LM. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms. *J Clin Psychiatry*, 2008;69(12):1856-9 [IF 5.060]
49. **Poyurovsky M**, Glick I, Koran L. Lamotrigine augmentation in schizophrenia patients with obsessive-compulsive symptoms. *Journal of Psychopharmacology* 2008 Dec 12, [Epub ahead of print] [IF 3.782]
50. Faragian S, Pashinian A, Fuchs C, **Poyurovsky M**. Obsessive-Compulsive Symptom Dimensions in Schizophrenia Patients with Comorbid Obsessive-Compulsive Disorder. *Prog Neuropsychopharmacol Biological Psychiatry* [IF 2.638] 2009;33(6):1009-12
51. **Poyurovsky M**, Glick I, Koran LM. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. *J Psychopharmacol*. 2010 Jun;24(6):861-6.
52. Bleich-Cohen M, Hendler T, Pashinian A, Faragian S, **Poyurovsky M**. Obsessive Musical Hallucinations in a Schizophrenia Patient: Psychopathological and fMRI Characteristics. *CNS Spectr*. 2011 Jul 1. pii: Bleich-Cohen. [Epub ahead of print]
53. Faragian S, Fuchs C, Pashinian A, Weizman R, Weizman A, **Poyurovsky M**. Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder. *Psychiatry Res*. 2012;197(1-2):19-22.
54. **Poyurovsky M**, Hermesh H., Weizman A. Fluvoxamine treatment in clozapine-induced obsessive compulsive symptoms in schizophrenic patients. *Clin Neuropharmacol*, 1996; 19:303-313 [IF 2.323]
55. **Poyurovsky M**, Bergman Y., Shoshani D., Schneidman M, Weizman A. Emergence of obsessive-compulsive symptoms and tics during clozapine withdrawal. *Clin Neuropharmacol* 1998; 21: 97-100. [IF 2.323]
56. **Poyurovsky M**, Isakov V., Hromnikov S., Modai I., Rauchverger B., Schneidman M., and Weizman A. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. *Int Clin Psychopharmacol* 1999; 14(2): 95-100. [IF 3.262]
57. **Poyurovsky M**, Fuchs K., Weizman A. Obsessive-compulsive symptoms in patients with first episode schizophrenia. *Am J Psychiatry* 1999; 156(12): 1998-2000. [IF 9.127]
58. **Poyurovsky M**, Dorfman-Etrog P, Hermesh H, Munitz H, Tollefson GD, Weizman A. Beneficial effect of olanzapine in schizophrenic patients with obsessive compulsive symptoms: case series. *Int Clin Psychopharmacol*, 2000; 15:169-173. [IF 3.262]

59. Silver H, Barash I, Aharon N, Kaplan A, **Poyurovsky M**. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. *Int Clin Psychopharmacol*. 2000;15(5):257-61. [IF 3.262]
60. **Poyurovsky M**, Hramenkov S, Isakov V, Rauchverger B, Modai I, Schneidman M, Fuchs C, Weizman A. Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia. *Psychiatry Res*. 2001;10: 49-57. [IF 2.298]
61. Baloush-Kleinman V, **Poyurovsky M**, Koren D, Schneidman M, Weizman A, Shnitt D. [Adherence to antipsychotic medication in schizophrenia patients] *Harefuah*. 2002 Dec; 141(12):1042-9, 1090. Hebrew.
62. **Poyurovsky M**, Kriss V, Weisman G, Faragian S, Kurs R, Schneidman M, Fuchs C, Weizman A, Weizman R. Comparison of Clinical Characteristics and Comorbidity in Schizophrenia Patients with and without Obsessive-Compulsive Disorder. *J Clin Psychiatry* 2003; 64 (11): 1300-130 [IF 5.060]
63. Nechmad A, Ratzoni G, **Poyurovsky M**, Meged S, Avidan G, Fuchs C, Bloch Y, Weizman R. Obsessive-compulsive disorder in adolescent schizophrenia patients. *Am J Psychiatry*. 2003 May; 160(5):1002-4. [IF 9.127]
64. **Poyurovsky M**, Bergman J, Weizman R. Obsessive-compulsive disorder in elderly schizophrenia patients. *J Psychiatr Res*. 2006;40(3):189-91 [IF 3.710]
65. Pashinian A, Faragian S, Levi A, Yeghiyan M, Gasparyan K, Weizman R, Weizman A, Fuchs C, **Poyurovsky M**. Obsessive-compulsive disorder in bipolar disorder patients with first manic episode. *J Affect Disord*. *J Affect Disord*. 2006 Aug;94(1-3):151-6. [IF 3.144]
66. **Poyurovsky M**, Faragian S, Pashinian A, Heidrach L., Fuchs C., Koran L. Clinical characteristics of schizotypal-related obsessive-compulsive disorder. *Psychiatry Res*, 2008 May 30;159(1-2):254-8. [IF 2.298]
67. **Poyurovsky M**, Faragian S, Shabeta A, Kosov A. Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder. *Psychiatry Res*, 2008 May 30;159(1-2):133-9. [IF 2.298]
68. **Poyurovsky M**, Kurs R, Weizman A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder. *J Clin Psychiatry*. 2003 May;64(5):611. [IF 5.060]
69. **Poyurovsky M**, Weizman A. Intravenous clomipramine for a schizophrenic patient with obsessive-compulsive symptoms. *Am J Psychiatry*. 1998 Jul;155(7):993. [IF 9.127]
70. **Poyurovsky M**, Weizman R, Weizman A, Koran L. Beneficial effect of the NMDA receptor antagonist memantine in treatment-resistant obsessive-compulsive disorder. *Am J Psychiatry*. 2005 Nov;162(11):2191-2 [IF 9.127]
71. **Poyurovsky M**. Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder. *Can J Psychiatry* 2007; 52(12): 692-693. [IF 3.026]
72. **Poyurovsky M**, Low-dose Clozapine in Treatment-Refractory Obsessive-Compulsive Disorder with Comorbid Schizotypal Personality Disorder. *Isr J Psychiatry Relat Sci*. 2009; 45 (3): 219-220 [IF 0.5]

## **Publications**

### Mental disorders: treatment

73. Maayan R, Shaltiel G, **Poyurovsky M**, Ramadan E, Morad O, Nechmad A, Weizman A, Agam G. Chronic lithium treatment affects rat brain and serum dehydroepiandrosterone (DHEA) and DHEA-sulphate (DHEA-S) levels. *Int J Neuropsychopharmacol*. 2004 Mar;7(1):71-5. [IF 4.895]
74. Koren D, Seidman LJ, **Poyurovsky M**, Goldsmith M, Viksman P, Zichel S, Klein E. The neuropsychological basis of insight in first-episode schizophrenia: a pilot metacognitive study. *Schizophr Res* 2004;70(2-3):195-202. [IF 4.240]
75. Koren D, **Poyurovsky M**, Seidman LJ, Goldsmith M, Wenger S, Klein EM. The neuropsychological basis of competence to consent in first-episode schizophrenia: a pilot metacognitive study. *Biol Psychiatry*. 2005 Mar 15;57(6):609-16. [IF 8.456]
76. **Poyurovsky M**, Fuchs C, Faragian S, Pashinian A. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: An add-on, double-blind placebo-controlled study. *Isr J Psychiatry* 2009;46(3):213-20. [IF 0.5]
77. Fuchs C, Steinberg M, **Poyurovsky M**. On the estimation and comparison of lifetime morbid risks. *Journal of Data Science*. 2010; 8: 645-664
78. Salomon R, Bleich-Cohen M, Hahamy-Dubossarsky A, Dinstien I, Weizman R, **Poyurovsky M**, Kupchik M, Kotler M, Hendler T, Malach R. Global functional connectivity deficits in schizophrenia depend on behavioral state. *J Neurosci*. 2011; 31(36):12972-81.
79. Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, **Poyurovsky M**. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. *Schizophr Res*. 2011 Aug;130(1-3):176-81.
80. Bleich-Cohen M, Sharon H, Weizman R, **Poyurovsky M**, Faragian S, Hendler T. Diminished language lateralization in schizophrenia corresponds to impaired inter-hemispheric functional connectivity. *Schizophr Res*. 2012; 134(2-3):131-6.
81. Klein E, Kolsky Y, **Poyurovsky M**, Koren D, Chistyakov A, Feinsod M. Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia. A double-blind sham-controlled pilot study. *Biol Psychiatry* 1999; 46(10): 1451-1454.
82. **Poyurovsky M**, Weizman A. Risperidone-induced nocturnal enuresis. *Isr J Psychiatry Relat Sci*. 1997;34(3):247-8. [IF 0.5]

### **Publications for patients and families**

Weizman A, **Poyurovsky M**, Tal V. **Schizophrenia**. Prologue Publishers, Rosh Ha'ayin, 1999.

Weizman A, **Poyurovsky M**, Tal V. **Bipolar disorder**. Prologue Publishers, Rosh Ha'ayin, 1999.